Compare Amylx Pharmaceuticals Inc (AMLX) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.71. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | VTIP | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | — |
52-Week High | $18.70 | $50.75 |
52-Week Low | $7.64 | $49.39 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
VTIP trades at $49.64, showing minimal daily movement with a slight decline of -0.04%. The ETF maintains a bullish technical signal overall, supported by oscillator readings, though moving averages indicate short-term bearish pressure. Recent institutional activity shows significant position increases by multiple financial firms, reflecting confidence in the inflation-protected bond strategy amid persistent inflation concerns.
As a short-term inflation-protected securities ETF, VTIP offers protection against rising costs with projected returns of 3.8% at current inflation rates. Key risks include interest rate sensitivity and Fed policy uncertainty, but institutional accumulation and inflation hedging demand provide support for defensive portfolio positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
